Involvement of the Acyl-CoA binding domain containing 7 in the control of food intake and energy expenditure in mice
- Université Laval, Canada
- Institut National de la Santé et de la Recherche Médicale, France
- Normandy University, France
Figures
Figure 1 with 3 supplements
Acbd7 mRNA sequence, distribution and processing in the mouse brain.
(a) Sequence of the Acbd7 mRNA open reading frame and the expected encoded protein. Additional codon and resulting amino acids are marked in red. (b,c) In situ hybridization showing Acbd7 mRNA distribution in mouse hypothalamus. Abbreviations: PVN, paraventricular nucleus; ARC, arcuate nucleus. Dashed lines indicate the boundaries of nuclei (d) Western blot performed on mediobasal hypothalamic homogenate using an ACBD7-specific antibody. MRM-MS analysis profile obtained using (e) synthetic NDN or (f) hypothalamic protein lysate as template. (g–j) Mediobasal hypothalamic sections labeled with ACBD7-specific antibody (g–m; brown labelling) and GFAP antibody (g,h; black labelling), POMC antibody (i,j; black labelling), NPY antibody (k,l; black labelling) or VGAT antibody (m,n; black labelling). (h,j,l,m) Higher magnification views of scare panels defined in (g), (i), (k) and (m) respectively. Apparent co-labelling is indicated by an arrow (j,n). (o,p) In situ hybridization analysis of Acbd7 mRNA levels in the ARC (o) and PVN (p) of ad libitum-fed mice, 18 hr-food deprived mice or 18 hr-food deprived mice having access to food 2 hr before sacrifice. Data were compared to ad libitum-fed mice as control (n=8). Data are expressed as mean ± SEM. One-way ANOVA, followed by a post-hoc multiple comparison Bonferroni test: ***p<0.001. (q,r) Western blot analysis of hypothalamic protein lysates from 18 hr-fasted mice or mice having access to food 6 hr before sacrifice, performed using ACBD7 and β-actin antibodies. (r) Quantification of the relative ACBD7 protein levels performed using β-actin signal as the loading control. (s) MRM-MS analysis of hypothalamic NDN peptide levels performed using exogenous peptide as control (n=4). Data are expressed as mean ± SEM. Unpaired Student’s t test: **p< 0.01; ***p<0.001.
-
Figure 1—source data 1
Synthetic NDN MRM-MS profile.
- https://doi.org/10.7554/eLife.11742.004
-
Figure 1—source data 2
Hypothalamic lysate MRM-MS profile.
- https://doi.org/10.7554/eLife.11742.005
-
Figure 1—source data 3
Impact of body energy status on ARC Acbd7 mRNA levels mRNA levels.
In situ hybridization source data.
- https://doi.org/10.7554/eLife.11742.006
-
Figure 1—source data 4
Impact of body energy status on PVN Acbd7 mRNA levels.
In situ hybridization source data.
- https://doi.org/10.7554/eLife.11742.007
-
Figure 1—source data 5
Impact of body energy status on hypothalamic ACBD7 levels.
Source data.
- https://doi.org/10.7554/eLife.11742.008
-
Figure 1—source data 6
Impact of body energy status on hypothalamic NDN levels.
MRM-MS quantification source data.
- https://doi.org/10.7554/eLife.11742.009
Figure 1—figure supplement 1
Acbd7 mRNA sequence and conservation.
Schematic representation of the organization of the coding DNA sequence of (a) the mouse Dbi/Acbp gene and (b) the mouse Acbd7 gene, underlining the selective pressure occurring on these two paralog genes. (c) Evolutionary conservation of the ACBD7 protein sequence. Amino acids allowing maturation of the whole protein, in expected bioactive fragments, are marked in red. (d) Homology between DBI/ACBP and both ACBD7-001 (i.e. ACBD788) and ACBD7-002 (i.e. ACBD789) expected proteins in mice. Conserved amino acids between both proteins are marked in red. Expected protein maturation products resulting from tryptic digestions are surrounded by a rectangle.
Figure 1—figure supplement 2
Relative Acbd7 mRNA levels in mice brain structures.
https://doi.org/10.7554/eLife.11742.011
Figure 1—figure supplement 3
ACBD7 labelling observed without prior colchicine or 3-MA treatment.
(A,B) Mediobasal hypothalamic sections incoming from colchicine or 3-MA untreated labeled with ACBD7-specific antibody. (B) Higher magnification views of scare panels defined in (A).
Figure 2
Effects of NDN on food intake and energy expenditure.
(a–c) Effects of icv injection of graded doses of NDN (a), ACBD788 (34-51) (b), and NDN(12-19) C-terminal fragment (c) on cumulative food intake in 18 hr-fasted mice. Mice were injected in the right ventricle with the indicated substance, diluted in aCSF as vehicle, and had access to food 20 min later (n=5, 6). Data are expressed as mean ± SEM. Two-way ANOVA followed by a post-hoc multiple comparison Bonferroni test: *p< 0.05; **p<0.01, ***p<0.001. (d) Comparison of the efficiency of each compound in terms of inhibiting food intake 3 hr after icv injection. (e,f) Effects of icv injection of NDN (10 ng) on energy expenditure in 18 hr-fasted mice. Energy expenditure as represented by area under the curve (AUC) between 12 and 18 hr (e; grey area; n=8). (g–j) Effects of icv injection of NDN (10 ng) on the O2 consumption (g; VO2), the production of CO2 (h; VCO2), the respiratory quotient (i; RQ) and the locomotor activity (j) during the first 6 hr following icv injection (n=8). (k) iBAT Ucp1 mRNA levels 4 hr after icv injection of NDN (10 ng) (n=7). Data are expressed as mean ± SEM. Unpaired Student’s t test: *p<0.05, **p<0.01, ***p<0.001.
-
Figure 2—source data 1
Impact of icv injection of NDN on food intake.
- https://doi.org/10.7554/eLife.11742.014
-
Figure 2—source data 2
Impact of icv injection of ACBD788(34-51) on food intake.
- https://doi.org/10.7554/eLife.11742.015
-
Figure 2—source data 3
Impact of icv injection of NDN(12-19) on food intake.
- https://doi.org/10.7554/eLife.11742.016
-
Figure 2—source data 4
Impact of icv injection of NDN on energy expenditure.
- https://doi.org/10.7554/eLife.11742.017
-
Figure 2—source data 5
Impact of icv injection of NDN on iBAT Ucp-1 mRNA levels.
- https://doi.org/10.7554/eLife.11742.018
Figure 3
Pharmacological characterization of the receptor relaying the anorexigenic effects of NDN.
Mice fasted for 18 hr received a single intraperitoneal injection of flumazenil (a; 10 mg/kg) or PK-11195 (b; 10 mg/kg) diluted in 0.9% NaCl solution, 20 min before icv injection of NDN (10 ng) or vehicle. Mice had access to food 20 min after injection and cumulative food intake was measured during the indicated periods (n=6). (c) Mice fasted for 18 hr were given icv injections of the endozepine metabotropic receptor antagonist cyclo1-8[DLeu5]ODN(11-18) (LV-1075; 100 ng) and NDN (10 ng) (n=6). Mice had access to food 20 min after icv injection and cumulative food intake was measured at the indicated periods. Data are expressed as mean ± SEM. Two-way ANOVA followed by a post-hoc multiple comparison Bonferroni test:*p< 0.05; **p<0.01, ***p<0.001.
-
Figure 3—source data 1
Impact of flumazenil treatment on the anorexigenic effect of NDN.
- https://doi.org/10.7554/eLife.11742.020
-
Figure 3—source data 2
Impact of PK-11195 treatment on the anorexigenic effect of NDN.
- https://doi.org/10.7554/eLife.11742.021
-
Figure 3—source data 3
Impact of LV-1075 treatment on the anorexigenic effect of NDN.
- https://doi.org/10.7554/eLife.11742.022
Figure 4
The melanocortin system relayes the anorexigenic effects of NDN.
(a–i) In situ hybridization analysis of Pomc mRNA levels in the mediobasal hypothalamic sections. Hypothalamic Pomc (a,b,c), AgRP (d,e,f) and Npy (g,h,i) mRNA levels from 18 hr-food deprived mice icv-injected with aCSF (a,d,g) or NDN (b,e,h; 100 ng) 2 hr before sacrifice. (c,f,i) Relative quantification performed in the ARC. Data were compared to aCSF injected mice as control (n=6, 7). Data are expressed as mean ± SEM. Unpaired Student’s t test: *p<0.05. (j) Mice fasted for 18 hr received icv injection of an MC4R-specific antagonist (HS024; 100 ng) alone or with NDN (10 ng) diluted in aCSF (n=5, 6). (k) Mc4r knock-out or wild type mice fasted for 18 hr were icv injected with NDN (10 ng). Mice had access to food 20 min after icv injection and cumulative food intake was measured at the indicated period (n=6). Data are expressed as mean ± SEM. Two-way ANOVA followed by a post-hoc multiple comparison Bonferroni test: *p< 0.05, **p<0.01, ***p<0.001. (l) Hypothalamic explants were preincubated in aCSF alone followed by an incubation with or without NDN (2 µg/ml). α-MSH released during incubation was normalized to the amount released during the preincubation period (n=5). Data are expressed as mean ± SEM. Unpaired t test: *p<0.05; NS, not statistically different. (m) Mice fasted for 18 hr were bilaterally injected in the MBH with NDN (1 ng). Mice had access to food 20 min after injection and cumulative food intake was measured at the indicated period (n=5). Data are expressed as mean ± SEM. Two-way ANOVA followed by a post-hoc multiple comparison Bonferroni test: *p< 0.05, **p<0.01, ***p<0.001.
-
Figure 4—source data 1
Impact of NDN on the hypothalamic Pomc, AgRP, and Npy mRNA levels.
- https://doi.org/10.7554/eLife.11742.024
-
Figure 4—source data 2
Impact of HS024 treatment on the anorexigenic effect of NDN.
- https://doi.org/10.7554/eLife.11742.025
-
Figure 4—source data 3
Impact of NDN on food intake in MC4R-KO mice.
- https://doi.org/10.7554/eLife.11742.026
-
Figure 4—source data 4
Impact of NDN on α-MSH release by hypothalamic explants.
- https://doi.org/10.7554/eLife.11742.027
-
Figure 4—source data 5
Impact of intra-MBH injection of NDN on food intake.
- https://doi.org/10.7554/eLife.11742.028
Figure 5
Hypothalamic NDN production is potentially involved in the leptin signaling pathway and the control of energy homeostasis.
(a,b) Western blot analysis of hypothalamic protein lysates from 18 hr-fasted mice icv-injected with aCSF (control) or leptin (Leptin; 2 µg) 2 hr before sacrifice, performed using ACBD7 and β-actin specific antibodies. Quantification of relative ACBD7 protein levels performed using β-actin signal as loading control (n=4). Data are expressed as mean ± SEM. Unpaired Student’s t test: ***p<0.001. (c) MRM-MS relative quantification of NDN levels in MBH explants harvested from 18 hr-fasted mice and icv-injected with aCSF, or with leptin (Leptin, 2 µg), 2 hr before sacrifice. Relative quantity was determined using exogenous peptide as an internal control (n=3). Data are expressed as mean ± SEM. Unpaired Student’s t test: *p<0.05. (d) Ad libitum-fed mice received icv injection of leptin (2 µg) with or without the endozepine metabotropic receptor antagonist cyclo1-8[DLeu5]ODN(11-18) (LV-1075; 1 µg) and/or the MC4R antagonist HS024 (100 ng), 2 hr before the beginning of the dark period, and food intake was measured after 4 hr (n=6). Data are expressed as mean ± SEM. One-way ANOVA followed by a post-hoc multiple comparison Bonferroni test using aCSF injected mice as control ***p<0.001; *p<0.05, or leptin injected mice as control # p<0.05, ### p<0.001. (e,f) Effect of two daily injections of NDN (100 ng/day) and LV-0175 (1 µg/day) on food intake (e) and body weight (f). Mice were injected each day at ZT2 and ZT10. Daily food intake (e) and body weight (f) were measured each day at ZT2 for 5 days (n=6). Data are expressed as mean ± SEM. Two-way ANOVA followed by a post-hoc multiple comparison Bonferroni test: *p< 0.05; **p<0.01, ***p<0.001.
-
Figure 5—source data 1
Impact of leptin treatment on hypothalamic ACBD7 protein levels.
- https://doi.org/10.7554/eLife.11742.030
-
Figure 5—source data 2
Impact of leptin treatment on hypothalamic NDN levels.
- https://doi.org/10.7554/eLife.11742.031
-
Figure 5—source data 3
Impact of acute pharmacological disruption of the EZ GPCR and the MC4R signaling pathways on the anorexigenic effect of leptin.
- https://doi.org/10.7554/eLife.11742.032
-
Figure 5—source data 4
Impact of chronic treatment (2 icv injections / day) of NDN on food intake.
- https://doi.org/10.7554/eLife.11742.033
-
Figure 5—source data 5
Impact of chronic treatment (2 icv injections / day) of NDN on body weight.
- https://doi.org/10.7554/eLife.11742.034
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Involvement of the Acyl-CoA binding domain containing 7 in the control of food intake and energy expenditure in mice
eLife 5:e11742.
https://doi.org/10.7554/eLife.11742
